A novel improved therapy strategy for diabetic nephropathy

References

• Yamagishi S, Fukami K, Ueda S, Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets 2007; 8:952 - 9; http://dx.doi.org/10.2174/138945007781386884; PMID: 17691932
   PubMed Web of Science ®Google Scholar
• Shah IM, Mackay SP, McKay GA. Therapeutic strategies in the treatment of diabetic nephropathy—a translational medicine approach. Curr Med Chem 2009; 16:997 - 1016; http://dx.doi.org/10.2174/092986709787581897; PMID: 19275608
   PubMed Web of Science ®Google Scholar
• Soldatos G, Cooper ME. Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res Clin Pract 2008; 82:Suppl 1 S75 - 9; http://dx.doi.org/10.1016/j.diabres.2008.09.042; PMID: 18994672
   PubMed Web of Science ®Google Scholar
• Suzuki D, Toyoda M, Yamamoto N, Miyauchi M, Katoh M, Kimura M, et al. Relationship between the expression of advanced glycation end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy. Intern Med 2006; 45:435 - 41; http://dx.doi.org/10.2169/internalmedicine.45.1557; PMID: 16679697
   PubMed Web of Science ®Google Scholar
• Fukami K, Yamagishi S, Ueda S, Okuda S. Role of AGEs in diabetic nephropathy. Curr Pharm Des 2008; 14:946 - 52; http://dx.doi.org/10.2174/138161208784139710; PMID: 18473844
   PubMed Web of Science ®Google Scholar
• Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44:129 - 46; http://dx.doi.org/10.1007/s001250051591; PMID: 11270668
   PubMed Web of Science ®Google Scholar
• Fukami K, Yamagishi S, Ueda S, Okuda S. Role of AGEs in diabetic nephropathy. Curr Pharm Des 2008; 14:946 - 52; http://dx.doi.org/10.2174/138161208784139710; PMID: 18473844
   PubMed Web of Science ®Google Scholar
• Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, Ramasamy R, et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 2003; 14:1383 - 95; http://dx.doi.org/10.1097/01.ASN.0000065100.17349.CA; PMID: 12707408
   PubMed Web of Science ®Google Scholar
• Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001; 27:535 - 42; PMID: 11694852
   PubMed Web of Science ®Google Scholar
• Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 2005; 83:876 - 86; http://dx.doi.org/10.1007/s00109-005-0688-7; PMID: 16133426
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994; 14:1521 - 8; http://dx.doi.org/10.1161/01.ATV.14.10.1521; PMID: 7918300
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res 2003; 23:129 - 34; PMID: 15224502
   PubMedGoogle Scholar
• Sourris KC, Forbes JM. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy—are these receptors valid therapeutic targets. Curr Drug Targets 2009; 10:42 - 50; http://dx.doi.org/10.2174/138945009787122905; PMID: 19149535
   PubMed Web of Science ®Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414:813 - 20; http://dx.doi.org/10.1038/414813a; PMID: 11742414
   PubMed Web of Science ®Google Scholar
• Fukami K, Cooper ME, Forbes JM. Agents in development for the treatment of diabetic nephropathy. Expert Opin Investig Drugs 2005; 14:279 - 94; http://dx.doi.org/10.1517/13543784.14.3.279; PMID: 15833059
   PubMed Web of Science ®Google Scholar
• Daroux M, Prévost G, Maillard-Lefebvre H, Gaxatte C, D’Agati VD, Schmidt AM, et al. Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies. Diabetes Metab 2010; 36:1 - 10; http://dx.doi.org/10.1016/j.diabet.2009.06.005; PMID: 19932633
   PubMed Web of Science ®Google Scholar
• Williams ME. New therapies for advanced glycation end product nephrotoxicity: current challenges. Am J Kidney Dis 2003; 41:Suppl 1 S42 - 7; http://dx.doi.org/10.1053/ajkd.2003.50083; PMID: 12612951
   PubMed Web of Science ®Google Scholar
• Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol Res 2010; 61:34 - 9; http://dx.doi.org/10.1016/j.phrs.2009.07.004; PMID: 19635564
   PubMed Web of Science ®Google Scholar
• Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun 2010; 391:1405 - 8; http://dx.doi.org/10.1016/j.bbrc.2009.12.075; PMID: 20026306
   PubMed Web of Science ®Google Scholar
• Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun 2009; 385:269 - 72; http://dx.doi.org/10.1016/j.bbrc.2009.05.061; PMID: 19460355
   PubMed Web of Science ®Google Scholar
• Humpert PM, Djuric Z, Kopf S, Rudofsky G, Morcos M, Nawroth PP, et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 2007; 6:9; http://dx.doi.org/10.1186/1475-2840-6-9; PMID: 17343760
   PubMed Web of Science ®Google Scholar
• Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006; 49:2756 - 62; http://dx.doi.org/10.1007/s00125-006-0394-1; PMID: 16969649
   PubMed Web of Science ®Google Scholar
• Patri AK, Myc A, Beals J, Thomas TP, Bander NH, Baker JR Jr. Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem 2004; 15:1174 - 81; http://dx.doi.org/10.1021/bc0499127; PMID: 15546182
   PubMed Web of Science ®Google Scholar
• Bhadra D, Yadav AK, Bhadra S, Jain NK. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int J Pharm 2005; 295:221 - 33; http://dx.doi.org/10.1016/j.ijpharm.2005.01.026; PMID: 15848007
   PubMed Web of Science ®Google Scholar
• Yang WJ, Cheng YY, Xu TW, Wang XY, Wen LP. Targeting cancer cells with biotin-dendrimer conjugates. Eur J Med Chem 2009; 44:862 - 8; http://dx.doi.org/10.1016/j.ejmech.2008.04.021; PMID: 18550227
   PubMed Web of Science ®Google Scholar
• Qiao WL, Wang BC, Wang YZ, Yang LC, Zhang YQ, Shao PY. Cancer Therapy Based on Nanomaterials and Nanocarrier Systems. J Nanomater 2010; http://dx.doi.org/10.1155/2010/796303
   Web of Science ®Google Scholar
• Balakumar P, Arora MK, Ganti SS, Reddy J, Singh M. Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions. Pharmacol Res 2009; 60:24 - 32; http://dx.doi.org/10.1016/j.phrs.2009.02.002; PMID: 19427582
   PubMed Web of Science ®Google Scholar
• Coughlan MT, Forbes JM, Cooper ME. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes. Kidney Int Suppl 2007; 106:S54 - 60; http://dx.doi.org/10.1038/sj.ki.5002387; PMID: 17653212
   PubMedGoogle Scholar
• Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007; 27:605 - 14; http://dx.doi.org/10.1159/000108104; PMID: 17823506
   PubMed Web of Science ®Google Scholar
• Khalifah RG, Chen Y, Wassenberg JJ. Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design. Ann N Y Acad Sci 2005; 1043:793 - 806; http://dx.doi.org/10.1196/annals.1333.092; PMID: 16037307
   PubMed Web of Science ®Google Scholar
• Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol Res 2010; 61:34 - 9; http://dx.doi.org/10.1016/j.phrs.2009.07.004; PMID: 19635564
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, et al. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc Res 2008; 75:130 - 4; http://dx.doi.org/10.1016/j.mvr.2007.05.001; PMID: 17560613
   PubMed Web of Science ®Google Scholar
• Caruso F, Susha AS, Giersig M, Mohwald H. Magnetic core-shell particles: preparation of magnetite multilayers on polymer latex microspheres. Adv Mater (Deerfield Beach Fla) 1999; 11:950 - 3; http://dx.doi.org/10.1002/(SICI)1521-4095(199908)11:11<950::AID-ADMA950>3.0.CO;2-T
   Web of Science ®Google Scholar
• Caruso F, Spasova M. Multilayer assemblies of silica-encapsulated gold nanoparticles on decomposable colloid templates. Adv Mater (Deerfield Beach Fla) 2001; 13:1090 - 4; http://dx.doi.org/10.1002/1521-4095(200107)13:14<1090::AID-ADMA1090>3.0.CO;2-H
   Web of Science ®Google Scholar
• Larsen G, Velarde-Ortiz R, Minchow K, Barrero A, Loscertales IG. A method for making inorganic and hybrid (organic/inorganic) fibers and vesicles with diameters in the submicrometer and micrometer range via sol-gel chemistry and electrically forced liquid jets. J Am Chem Soc 2003; 125:1154 - 5; http://dx.doi.org/10.1021/ja028983i; PMID: 12553802
   PubMed Web of Science ®Google Scholar
• Mu L, Feng SS. Fabrication, characterization and in vitro release of paclitaxel (Taxol) loaded poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers. J Control Release 2001; 76:239 - 54; http://dx.doi.org/10.1016/S0168-3659(01)00440-0; PMID: 11578739
   PubMed Web of Science ®Google Scholar
• Fahmy TM, Fong PM, Goyal A, Saltzman WM. Targeted for drug delivery. Mater Today 2005; 8:18 - 26; http://dx.doi.org/10.1016/S1369-7021(05)71033-6
   Web of Science ®Google Scholar
• Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 2007; 120:18 - 26; http://dx.doi.org/10.1016/j.jconrel.2007.03.012; PMID: 17509712
   PubMed Web of Science ®Google Scholar